MedTrace Logo

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

NCT02333045 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-01-19

Study results available
· View outcomes & findings →

Summary

This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV infection.

Conditions

Interventions

DRUG

Truvada qd

Truvada 1 tablet PO daily for 7 days

DRUG

Maraviroc 300 qd

Maraviroc 300 mg PO daily for 7 days

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Anandi Sheth, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-10-28
Completion
2016-10-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333045 on ClinicalTrials.gov